Epicutaneous tolerability of an innovative foam formulation of thiocolchicoside in healthy volunteers

Roberto Novellini, C. Fattore, G. Fedele, M. P. Ferrari

Research output: Contribution to journalArticle

Abstract

Objective: To investigate the local tolerability of an innovative formulation of 0.25% thiocolchicoside foam in comparison with a commercially available 0.25% thiocolchicoside cream after epicutaneous application in healthy subjects. Design: Single-centre, non-blind, two-period, randomised, crossover trial. Setting: Bourn Hall Clinic in Bourn, Cambridge, UK. Study participants: 25 healthy volunteers (including one replacement subject): 13 females and 12 males, age range 21 to 56 years. Interventions: Application of either thiocolchicoside foam or cream three times daily for 5 days on a 15 × 10cm area on the upper back of each subject. Main outcome measures and results: The primary endpoint was the local tolerability of the foam formulation in comparison with the reference product. Both products were well tolerated and no serious or severe adverse events were observed. A maculopapular rash in the treatment area led to premature withdrawal of treatment on two occasions after application of the cream and on one occasion after application of the foam. Local mild erythema and itching were the most frequent adverse events. At per-protocol analysis by ANOVA, scores for erythema, oedema, itching and local pain did not show significant differences between the two formulations, although there was a trend for itching to occur more commonly and to be more marked with the cream (p = 0.06). Additional post-hoc analysis showed a significant temporal trend only for the cream. No significant changes in safety laboratory tests were found between pre- and post-study evaluations. Conclusions: The local tolerability of the innovative foam formulation is comparable with or better than that of the reference product.

Original languageEnglish
Pages (from-to)233-240
Number of pages8
JournalClinical Drug Investigation
Volume22
Issue number4
Publication statusPublished - 2002

Fingerprint

Pruritus
Healthy Volunteers
Erythema
Exanthema
Cross-Over Studies
Edema
Analysis of Variance
Outcome Assessment (Health Care)
Safety
Pain
Therapeutics
thiocolchicoside

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Epicutaneous tolerability of an innovative foam formulation of thiocolchicoside in healthy volunteers. / Novellini, Roberto; Fattore, C.; Fedele, G.; Ferrari, M. P.

In: Clinical Drug Investigation, Vol. 22, No. 4, 2002, p. 233-240.

Research output: Contribution to journalArticle

@article{95660e33801644b59c275c5862be5ded,
title = "Epicutaneous tolerability of an innovative foam formulation of thiocolchicoside in healthy volunteers",
abstract = "Objective: To investigate the local tolerability of an innovative formulation of 0.25{\%} thiocolchicoside foam in comparison with a commercially available 0.25{\%} thiocolchicoside cream after epicutaneous application in healthy subjects. Design: Single-centre, non-blind, two-period, randomised, crossover trial. Setting: Bourn Hall Clinic in Bourn, Cambridge, UK. Study participants: 25 healthy volunteers (including one replacement subject): 13 females and 12 males, age range 21 to 56 years. Interventions: Application of either thiocolchicoside foam or cream three times daily for 5 days on a 15 × 10cm area on the upper back of each subject. Main outcome measures and results: The primary endpoint was the local tolerability of the foam formulation in comparison with the reference product. Both products were well tolerated and no serious or severe adverse events were observed. A maculopapular rash in the treatment area led to premature withdrawal of treatment on two occasions after application of the cream and on one occasion after application of the foam. Local mild erythema and itching were the most frequent adverse events. At per-protocol analysis by ANOVA, scores for erythema, oedema, itching and local pain did not show significant differences between the two formulations, although there was a trend for itching to occur more commonly and to be more marked with the cream (p = 0.06). Additional post-hoc analysis showed a significant temporal trend only for the cream. No significant changes in safety laboratory tests were found between pre- and post-study evaluations. Conclusions: The local tolerability of the innovative foam formulation is comparable with or better than that of the reference product.",
author = "Roberto Novellini and C. Fattore and G. Fedele and Ferrari, {M. P.}",
year = "2002",
language = "English",
volume = "22",
pages = "233--240",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Epicutaneous tolerability of an innovative foam formulation of thiocolchicoside in healthy volunteers

AU - Novellini, Roberto

AU - Fattore, C.

AU - Fedele, G.

AU - Ferrari, M. P.

PY - 2002

Y1 - 2002

N2 - Objective: To investigate the local tolerability of an innovative formulation of 0.25% thiocolchicoside foam in comparison with a commercially available 0.25% thiocolchicoside cream after epicutaneous application in healthy subjects. Design: Single-centre, non-blind, two-period, randomised, crossover trial. Setting: Bourn Hall Clinic in Bourn, Cambridge, UK. Study participants: 25 healthy volunteers (including one replacement subject): 13 females and 12 males, age range 21 to 56 years. Interventions: Application of either thiocolchicoside foam or cream three times daily for 5 days on a 15 × 10cm area on the upper back of each subject. Main outcome measures and results: The primary endpoint was the local tolerability of the foam formulation in comparison with the reference product. Both products were well tolerated and no serious or severe adverse events were observed. A maculopapular rash in the treatment area led to premature withdrawal of treatment on two occasions after application of the cream and on one occasion after application of the foam. Local mild erythema and itching were the most frequent adverse events. At per-protocol analysis by ANOVA, scores for erythema, oedema, itching and local pain did not show significant differences between the two formulations, although there was a trend for itching to occur more commonly and to be more marked with the cream (p = 0.06). Additional post-hoc analysis showed a significant temporal trend only for the cream. No significant changes in safety laboratory tests were found between pre- and post-study evaluations. Conclusions: The local tolerability of the innovative foam formulation is comparable with or better than that of the reference product.

AB - Objective: To investigate the local tolerability of an innovative formulation of 0.25% thiocolchicoside foam in comparison with a commercially available 0.25% thiocolchicoside cream after epicutaneous application in healthy subjects. Design: Single-centre, non-blind, two-period, randomised, crossover trial. Setting: Bourn Hall Clinic in Bourn, Cambridge, UK. Study participants: 25 healthy volunteers (including one replacement subject): 13 females and 12 males, age range 21 to 56 years. Interventions: Application of either thiocolchicoside foam or cream three times daily for 5 days on a 15 × 10cm area on the upper back of each subject. Main outcome measures and results: The primary endpoint was the local tolerability of the foam formulation in comparison with the reference product. Both products were well tolerated and no serious or severe adverse events were observed. A maculopapular rash in the treatment area led to premature withdrawal of treatment on two occasions after application of the cream and on one occasion after application of the foam. Local mild erythema and itching were the most frequent adverse events. At per-protocol analysis by ANOVA, scores for erythema, oedema, itching and local pain did not show significant differences between the two formulations, although there was a trend for itching to occur more commonly and to be more marked with the cream (p = 0.06). Additional post-hoc analysis showed a significant temporal trend only for the cream. No significant changes in safety laboratory tests were found between pre- and post-study evaluations. Conclusions: The local tolerability of the innovative foam formulation is comparable with or better than that of the reference product.

UR - http://www.scopus.com/inward/record.url?scp=0036242520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036242520&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 233

EP - 240

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 4

ER -